Key result
A systematic compilation of health economic evidence for heart disease treatments found cost-effectiveness ratios ranging from dominant to over 1,000,000 Euros per QALY gained.
Why the study?
What are the cost-effectiveness ratios for different intervention strategies in the treatment of heart diseases?
Systematic Review
What are the cost-effectiveness ratios for different intervention strategies in the treatment of heart diseases?
This systematic review provides a comprehensive ranking table of cost-effectiveness ratios for various cardiovascular interventions to aid decision-makers in resource allocation.
Answers are grounded in this paper and cite their sources.
Variable cost-effectiveness ratios support selective adoption of interventions; extends economic syntheses with a ranked compilation for decision-makers.
OBJECTIVES: Despite the continuing interest in health economic research, we could find no accessible data set on cost-effectiveness, useful as practical information to decision makers who must allocate scarce resources within the cardiovascular field. The aim of this paper was to present cost-effectiveness ratios, based on a systematic literature search for the treatment of heart diseases. DESIGN: A comprehensive literature search on cost-effectiveness analyses of intervention strategies for the treatment of heart diseases was conducted. We compiled available cost-effectiveness ratios for different heart conditions and treatment strategies, in a cost-effectiveness ranking table. The cost-effectiveness ratios were expressed as a cost per quality adjusted life year (QALY) or life year gained. RESULTS: Cost-effectiveness ratios, ranging from dominant to those costing more than 1,000,000 Euros per QALY gained, and bibliographic references are provided for. The table was categorized according to disease group, making the ranking table readily available. CONCLUSIONS: Cost-effectiveness ranking tables provide a means of presenting cost-effectiveness evidence. They provide valid information within a limited space aiding decision makers on the allocation of health care resources. This paper represents an extensive compilation of health economic evidence for the treatment of heart diseases.
No takes yet. Share an insight, caveat, or question.
Eckard et al. (2011) conducted a systematic review in Heart diseases. Intervention strategies for the treatment of heart diseases was evaluated on Cost-effectiveness ratios (cost per QALY or life year gained). A systematic compilation of health economic evidence for heart disease treatments found cost-effectiveness ratios ranging from dominant to over 1,000,000 Euros per QALY gained.
Synapse has enriched 10 related papers. Consider them for comparative context: